Analysis Group Experts to Present HEOR and Epidemiology Research at AMCP Nexus Meeting

October 7, 2025

Analysis Group’s HEOR, Epidemiology & Market Access practice will present 19 posters, including a gold ribbon awardee, at the Academy of Managed Care Pharmacy’s (AMCP’s) annual Nexus meeting, which will be held October 27–30, 2025, in National Harbor, MD.

Gold Ribbon

• “Healthcare resource utilization and costs among individuals with narcolepsy and idiopathic hypersomnia in the United States,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin and Vice President Patrick S. Gagnon – in collaboration with researchers from CardioSleep Diagnostics; Indiana University School of Medicine; University of California, San Diego; and Jazz Pharmaceuticals (sponsor). Wednesday, October 29, 12:00–1:00p.m. Poster 80.

Additional poster presentations include:

• “Longitudinal assessment of treatment costs in patients with spinal muscular atrophy receiving disease-modifying therapies,” coauthored by an Analysis Group team – including Managing Principal Min Yang and Manager Wei Song – in collaboration with researchers from Novartis (sponsor). Wednesday, October 29, 12:00–1:00p.m. Poster 74.
  
  
• “Real-world treatment patterns in patients with psoriasis receiving tildrakizumab compared to ustekinumab,” coauthored by an Analysis Group team – including Managing Principal Mihran Yenikomshian and Vice Presidents Lynn Huynh and Enrico Zanardo – in collaboration with the Zucker School of Medicine, Viver Health, and Sun Pharmaceutical Industries (sponsor). Wednesday, October 29, 12:00–1:00p.m. Poster 98.
  
  
• “Economic burden of moderate-to-severe chronic hand eczema in the United States: A retrospective claims analysis,” coauthored by an Analysis Group Team – including Managing Principal Annie Guérin, Vice President Marjolaine Gauthier-Loiselle, and Manager Rebecca Burne – in collaboration with the University of California and LEO Pharma (sponsor). Wednesday, October 29, 12:00–1:00p.m. Poster 105.
  
  
• “Modelling Total Healthcare Cost Offsets and Treatment Costs Associated with Treating Adults with Obesity with Tirzepatide and Semaglutide in US Clinical Practice Settings,” coauthored by an Analysis Group team – including Managing Principal Noam Kirson, Vice President Urvi Desai, and Manager Nicolae Done – in collaboration with University College Dublin and Eli Lilly (sponsor). Wednesday, October 29, 12:00–1:00p.m. Poster 151.
  
  
• “The economic burden of immune thrombocytopenia in the United States: insights from a systematic literature review and key evidence gaps,” coauthored by an Analysis Group team – including Principal Dave Nellesen and Manager Samantha Kaufhold – in collaboration with Weill Cornell Medicine, New York-Presbyterian, and Novartis (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 230.
  
  
• “An economic model assessing costs, relapses, and antipsychotic adherence of switching Medicaid beneficiaries with schizophrenia from oral antipsychotics to once-monthly, once-every-three-months, and once-every-six-months paliperidone palmitate,” coauthored by an Analysis Group team – including Vice President Dominic Pilon and Manager Laura Morrison – in collaboration with Johnson & Johnson (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 280.
  
  
• “Economic burden of recurrence in early-stage hepatocellular carcinoma (HCC) treated with curative intent: A retrospective analysis of SEER-Medicare data,” coauthored by an Analysis Group team – including Vice President Yan Song, and Managers Emily Gao and Angela Lax – in collaboration with the University of California, San Francisco, and Merck (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 300.
  
  
• “Real-world analysis of health care resource utilization and costs among patients with high-risk non–muscle-invasive bladder cancer with papillary-only disease who are unresponsive to Bacillus Calmette-Guérin treatment using SEER-Medicare data,” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, and Manager Carmine Rossi – in collaboration with Stanford University School of Medicine, Urology of Virginia, and Johnson & Johnson (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 304.
  
  
• “Real-world analysis of treatment patterns and disease recurrence among patients with high-risk non–muscle-invasive bladder cancer with papillary-only disease who are unresponsive to Bacillus Calmette-Guérin therapy using SEER-Medicare data,” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, and Manager Carmine Rossi – in collaboration with Stanford University School of Medicine, Urology of Virginia, and Johnson & Johnson (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 305.
  
  
• “Healthcare resource utilization and costs of patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ who are unresponsive to Bacillus Calmette-Guérin treatment: A real-world analysis using SEER-Medicare data,” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, and Manager Carmine Rossi – in collaboration with Stanford University School of Medicine, Urology of Virginia, and Johnson & Johnson (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 322.
  
  
• “Treatment patterns and disease recurrence among patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ who are unresponsive to Bacillus Calmette-Guérin treatment: A real-world analysis using SEER-Medicare data,” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, and Manager Carmine Rossi – in collaboration with Stanford University School of Medicine, Urology of Virginia, and Johnson & Johnson (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 325.
  
  
• “Real world assessment of manic events among patients with bipolar I disorder treated with cariprazine versus other atypical antipsychotics,” coauthored by an Analysis Group team – including Principal François Laliberté and Vice President Enrico Zanardo – in collaboration with the Brain and Cognition Discovery Foundation, and AbbVie (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 353.
  
  
• “Healthcare Resource Utilization in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Study Results,” coauthored by an Analysis Group team – including Managing Principal Elyse Swallow and Vice President Debbie Goldschmidt – in collaboration with the Miami Cancer Institute, Johns Hopkins School of Medicine; Texas Oncology, Baylor Scott & White Charles A. Sammons Cancer Center, and Sobi (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 359.
  
  
• “Real-World Clinical Outcomes and Disease Management Costs among High-Risk Non-Muscle Invasive Bladder Cancer Patients Treated with Bacillus Calmette-Guérin: A SEER-Medicare Analysis,” coauthored by an Analysis Group team – including Vice Presidents Wei Gao and Yan Song, and Manager Honghao Fang – in collaboration with the University of Texas Southwestern Medical Center and Merck (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 360.
• “Mapping the Cirrhosis Journey: Cirrhosis Etiologies and Rates, Timing, and Cost of Complications in a US claims database,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Patrick S. Gagnon, and Managers Rebecca Burne and Thomas Cornwall – in collaboration with Weill Cornell Medicine and Bausch Health (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 365.
  
  
• “Burden of anti-seizure medication titration on health care resource utilization and costs among patients with focal onset seizures: A physician panel-based chart review,” coauthored by an Analysis Group team – including Vice President Bruno Émond and Manager Carmine Rossi – in collaboration with the University of Wisconsin-Madison and Xenon Pharmaceuticals (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 369.
  
  
• “Economic burden among patients with high-risk and low-to-intermediate-risk localized prostate cancer receiving radical prostatectomy in the United States,” coauthored by an Analysis Group team – including Vice President Dominic Pilon and Manager Carmine Rossi – in collaboration with Chesapeake Urology and Johnson & Johnson (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 384.
  
  
• “Real-world treatment history and economic outcomes of CD38 antibody-based regimens in relapsed/refractory multiple myeloma in the United States,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, and Manager Honghao Fang – in collaboration with Sanofi (sponsor). Wednesday, October 29, 1:00–2:00p.m. Poster 385.